Moody Aldrich Partners LLC lifted its stake in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 48.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 31,956 shares of the company’s stock after buying an additional 10,430 shares during the quarter. Aerie Pharmaceuticals comprises 1.5% of Moody Aldrich Partners LLC’s portfolio, making the stock its 19th largest position. Moody Aldrich Partners LLC’s holdings in Aerie Pharmaceuticals were worth $1,909,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in shares of Aerie Pharmaceuticals by 55.0% during the second quarter. Vanguard Group Inc. now owns 2,158,825 shares of the company’s stock valued at $113,446,000 after buying an additional 766,300 shares during the period. Bank of New York Mellon Corp boosted its stake in Aerie Pharmaceuticals by 25.9% during the third quarter. Bank of New York Mellon Corp now owns 550,275 shares of the company’s stock worth $26,743,000 after acquiring an additional 113,320 shares in the last quarter. Columbus Circle Investors boosted its stake in Aerie Pharmaceuticals by 41.0% during the third quarter. Columbus Circle Investors now owns 519,806 shares of the company’s stock worth $25,263,000 after acquiring an additional 151,133 shares in the last quarter. Northern Trust Corp boosted its stake in Aerie Pharmaceuticals by 6.6% during the second quarter. Northern Trust Corp now owns 405,116 shares of the company’s stock worth $21,289,000 after acquiring an additional 25,254 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in Aerie Pharmaceuticals by 67.1% during the third quarter. Russell Investments Group Ltd. now owns 388,666 shares of the company’s stock worth $18,889,000 after acquiring an additional 156,056 shares in the last quarter.

Several equities research analysts recently commented on the stock. Mizuho reissued a “buy” rating and set a $87.00 price objective on shares of Aerie Pharmaceuticals in a research note on Monday. Canaccord Genuity reissued a “buy” rating and set a $86.00 price objective (up previously from $73.00) on shares of Aerie Pharmaceuticals in a research note on Thursday, January 25th. BidaskClub raised shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 23rd. Seaport Global Securities assumed coverage on shares of Aerie Pharmaceuticals in a research note on Friday, January 26th. They set a “buy” rating and a $78.00 price objective on the stock. Finally, Needham & Company LLC reissued a “buy” rating and set a $76.00 price objective (up previously from $65.00) on shares of Aerie Pharmaceuticals in a research note on Monday, October 16th. Four investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $73.27.

Aerie Pharmaceuticals Inc (AERI) opened at $54.85 on Thursday. The firm has a market cap of $2,120.27, a P/E ratio of -16.42 and a beta of 1.11. Aerie Pharmaceuticals Inc has a 52-week low of $38.14 and a 52-week high of $66.60. The company has a current ratio of 15.24, a quick ratio of 15.24 and a debt-to-equity ratio of 0.78.

Aerie Pharmaceuticals (NASDAQ:AERI) last issued its quarterly earnings data on Wednesday, November 8th. The company reported ($0.89) earnings per share for the quarter. equities analysts expect that Aerie Pharmaceuticals Inc will post -3.97 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Aerie Pharmaceuticals Inc (AERI) Shares Bought by Moody Aldrich Partners LLC” was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://theolympiareport.com/2018/02/01/aerie-pharmaceuticals-inc-aeri-shares-bought-by-moody-aldrich-partners-llc.html.

Aerie Pharmaceuticals Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals Inc (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.